Hansen Lin, Liangmin Fu, Xinwei Zhou, Anze Yu, Yuhang Chen, Wuyuan Liao, Guannan Shu, Lizhen Zhang, Lei Tan, Hui Liang, Zhu Wang, Qiong Deng, Jieyan Wang, Meiyu Jin, Zhenhua Chen, Jinhuan Wei, Jiazheng Cao, Wei Chen, Xiaofei Li, Pengju Li, Jun Lu, Junhang Luo
The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only beneficial for a minority of patients with BLCA, and drug resistance is a barrier to achieving significant clinical effects of anti-programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) therapy. In this study, higher low-density lipoprotein receptor-related protein 1 (LRP1) levels were related to a poorer prognosis for patients with various cancers, including those with higher grades and later stages of BLCA...
March 8, 2024: Cancer Letters